FINWIRES · TerminalLIVE
FINWIRES

HKG:9637

6 stories mentioning HKG:9637Updated 6d ago

Every FINWIRES story that references HKG:9637, newest first.

Asia

Alebund Pharma Nets HK$185 Million From Full Exercise of IPO Over-Allotment Option

Alebund Pharmaceuticals (Jiangsu) (HKG:9637) said the over-allotment option of its Hong Kong initial public offering was fully exercised on Friday, according to a same-day Hong Kong bourse filing.The biopharmaceutical company expects to raise about HK$184.7 million in additional net proceeds.The exercise involved the issue of 8.51 million additional H-shares at HK$22.60 each, representing about 15% of the total offer shares available under the global offering.Dealings in the over-allotment shares are expected to begin on July 29, the filing said.

HKG:9637
Asia

Alebund Pharma Doses First Patient in Global Phase 2b Hyperphosphatemia Trial

Alebund Pharmaceuticals (HKG:9637) said that the first participant has been randomized and dosed in a global phase 2b clinical trial evaluating AP306 for hyperphosphatemia in patients receiving maintenance hemodialysis, according to a Tuesday Hong Kong bourse filing.The multicenter, randomized, double-blind, placebo-controlled study is being conducted at sites in the U.S. and China and plans to enroll about 168 participants.Topline results are expected in the first half of 2027, the filing said.

HKG:9637
Asia

Alebund Pharmaceuticals Jumps 86% in Hong Kong Trading Debut

Alebund Pharmaceuticals (Jiangsu)'s (HKG:9637) shares opened 86% above the offer price in a strong Hong Kong debut on Monday morning.The biopharmaceutical company opened at HK$42.00 per share, well above the offer price of HK$22.60.

HKG:9637
Asia

Alebund Pharmaceuticals Nets HK$1.2 Billion in Hong Kong IPO

Alebund Pharmaceuticals (Jiangsu) (HKG:9637) raised HK$1.18 billion in net proceeds from its initial public offering in Hong Kong, according to a Friday after-market filing on the Hong Kong Exchange.The biopharmaceutical company priced its IPO at HK$22.60 per share, issuing roughly 56.8 million shares.The Hong Kong public offering portion of the deal was 963.56 times subscribed, with a final allocation of 5.68 million shares.The international offering was 19.77 times subscribed, with 51.08 million shares allocated.Cornerstone investors were allotted 28.3 million shares, accounting for 49.78% of the IPO shares.Alebund Pharma is set to debut on the Hong Kong bourse today, June 29.

HKG:9637
Asia

Hong Kong Stocks Extend Losses Following US Fed's Hawkish Pause; Three Firms File for IPO

Hong Kong stocks slumped on their last trading day of the week as investors reacted to the U.S. Federal Reserve's decision to hold interest rates with the possibility of a single rate hike by the end of 2026.The Hang Seng Index fell by around 387.35 points, or roughly 1.6%, to end at 23,924.81, while the Hang Seng China Enterprises Index decreased by 167.99 points, or 2.1%, to end at 7,976.04.Hong Kong markets will be closed Friday on account of a public holiday.The Federal Reserve kept its monetary policy steady Wednesday, removing the so-called easing bias from its statement, while raising its interest rate expectations through 2028. The central bank's Federal Open Market Committee maintained its interest rate at 3.50% to 3.75%, in line with Wall Street's expectations and marking its fourth consecutive pause.Fed Chair Kevin Warsh said the central bank would "deliver price stability" and acknowledged inflation has remained above the Fed's 2% target for years.In the same vein, the Hong Kong Monetary Authority kept its base rate unchanged at 4%.The authority said the outlook for U.S. interest rates remains uncertain and urged the public to carefully assess and manage interest-rate risks when making property purchases, investment decisions, or borrowing arrangements.Meanwhile, the city is seeking to raise HK$3 billion through tenders for institutional government bonds to fund infrastructure projects.In corporate news, three firms filed to go public in Hong Kong.Among the future debutants, Alebund Pharmaceuticals (HKG:9637) is seeking to raise HK$1.28 billion to fund the clinical development of its drug pipeline, while Crealights Technology (HKG:1191) is targeting HK$1.53 billion to expand its production capacity for optical transceivers.Meanwhile, Baige Online Digital Technology (HKG:2672) is seeking to raise up to HK$676.2 million to expand its research and development capabilities.

Hang SengHKG:1191HKG:2672HKG:9637
Asia

Alebund Pharmaceuticals Launches HK$1.3 Billion Hong Kong IPO

Alebund Pharmaceuticals (HKG:9637) launched its Hong Kong initial public offering on Thursday, seeking to raise about HK$1.28 billion.The China-based biopharmaceutical company is offering 56.8 million H shares at HK$22.60 each, according to a Hong Kong bourse filing.The offering comprises 5.7 million shares for Hong Kong investors and 51.1 million shares for international investors, subject to reallocation and the over-allotment option.The company is expected to announce allocation results on June 26, ahead of its planned trading debut on June 29.Net proceeds will be used primarily to fund the clinical development and regulatory approval of Alebund Pharmaceuticals' pipeline candidates, including AP301, AP306, AP303, and AP308.The company also plans to use the funds to advance preclinical research, expand manufacturing capacity, support future commercialization efforts, and provide working capital and general corporate purposes.The listing has 11 cornerstone investors, including GIC, Loomis Sayles, RTW Funds, Tencent, and Cormorant, which committed to subscribing to $81.5 million worth of shares.The investors agreed to take up 28.3 million shares, or 49.8% of the offering, according to the prospectus.Jefferies Hong Kong, Merrill Lynch (Asia Pacific) and Huatai Financial Holdings (Hong Kong) are acting as joint sponsors, sponsor-overall coordinators, joint representatives, overall coordinators, joint global coordinators, joint bookrunners and joint lead managers.CLSA is serving as a joint representative, overall coordinator, joint global coordinator, joint bookrunner, and joint lead manager, while BOCI Asia is acting as an overall coordinator, joint global coordinator, joint bookrunner, and joint lead manager.

HKG:9637

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:9637 in your portfolio
WheelAI
WheelAI
Analyze HKG:9637 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:9637